Skip to main content

Biosynex takes up residence in Delémont

Biosynex founders
| News

Biosynex takes up residence in Delémont


The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for COVID-19. It has had a site in Delémont since the start of the year and plans to continue on its growth course from there.

Biosynex founders
Thierry Paper (Deputy Managing Director), Larry Abensur (CEO), Thomas Lamy (Deputy Managing Director)

Biosynex specializes in rapid tests and has launched numerous products for women over recent years, such as fertility tests and pregnancy tests. The French firm with headquarters in Illkirch-Graffenstaden in the Alsace region of France also launched a rapid test for COVID-19 last year, which is being manufactured in France. In order to respond to increasing demand from Switzerland, Biosynex has decided to set up a branch there and is now established in Delémont.

Back in 2018, Fribourg was the original destination for Biosynex’s Swiss branch. However, at the start of 2021, the move was made to Delémont and thus to the Basel Area. According to CEO Larry Abensur, firstly, the proximity to Alsace was one plus point for the location in Jura, but the favorable environment for companies in the life sciences sector in particular, with the “efficient laboratories, academic and private research centers” it provides, was another reason for the new location. In Delémont, Biosynex now not only has the desired infrastructure with offices and storage all in one building, it is also in a position to achieve its new growth targets from its location in Delémont. These have become significantly more ambitious since 2018.

The four acquisitions Biosynex has made over the past four years are testament to this. One such acquisition was of the American company ProciseDx, which develops products for gastroenterology (relating to disorders of the digestive system). Biosynex was founded in 2005 and currently employs over 200 members of staff. Its products are sold in 60 countries.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.